Microbial induced calcite precipitation can consolidate martian and lunar regolith simulants.

We demonstrate that Microbial Induced Calcite Precipitation (MICP) can be utilized for creation of consolidates of Martian Simulant Soil (MSS) and Lunar Simulant Soil (LSS) in the form of a 'brick'. A urease producer bacterium, Sporosarcina pasteurii, was used to induce the MICP process for the both simulant soils. An admixture of guar gum as an organic polymer and NiCl2, as bio- catalyst to enhance urease activity, was introduced to increase the compressive strength of the biologically grown bricks. A casting method was utilized for a slurry consisting of the appropriate simulant soil and microbe; the slurry over a few days consolidated in the form of a 'brick' of the desired shape. In case of MSS, maximum strength of 3.3 MPa was obtained with 10mM NiCl2 and 1% guar gum supplementation whereas in case of LSS maximum strength of 5.65 Mpa was obtained with 1% guar gum supplementation and 10mM NiCl2. MICP mediated consolidation of the simulant soil was confirmed with field emission scanning electron microscopy (FESEM), X-ray diffraction (XRD) and thermogravimetry (TG). Our work demonstrates a biological approach with an explicit casting method towards manufacturing of consolidated structures using extra-terrestrial regolith simulant; this is a promising route for in situ development of structural elements on the extra-terrestrial habitats.

Review of current clinical management guidelines for COVID-19 with special reference to India.

The healthcare sector has been overwhelmed by the global rise in the number of COVID-19 cases. The primary care physicians at the forefront of this pandemic are being provided with multiple guidelines (state, national, international). The aim of this review was to examine the existing guidelines for congruence and critically analyze them in light of current evidence. A discordance was noted between the national and state guidelines with respect to indication, duration and dosage of antivirals, steroids/immunomodulators, anticoagulation and convalescent plasma. The lack of concordance between various guidelines mandates the need for a unified national guideline that is regularly updated.

Advancing nutritional therapy: A novel polymeric formulation attenuates intestinal inflammation in a murine colitis model and suppresses pro-inflammatory cytokine production in ex-vivo cultured inflamed colonic biopsies.

BACKGROUND & AIMS: Nutritional therapy is a viable therapeutic option for the treatment of Crohn disease (CD). Therefore improving nutritional therapy would greatly benefit CD patients. The aim of this study was to define the anti-inflammatory properties of a novel nutritional polymeric formula (PF) in comparison to a currently available standard PF. METHODS: Dextran sodium sulfate (DSS) was utilized to induce colitis in C57BL/6 mice with mice randomized to receive either standard PF or novel PF in addition to control groups. Changes in body weight were recorded and colonic damage was assessed histologically and biochemically. Additional experiments were also included where the cytokine response of colonic biopsies from pediatric CD patients was measured following exposure to standard PF or novel PF. RESULTS: DSS induced significant body weight loss, morphological changes in the colon, increased myeloperoxidase (MPO) activity and up-regulated colonic mRNA expression of tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-12 and monocyte chemoattractant protein (MCP)-1, as well as associated histological changes. Other than histological damage, these inflammatory changes were reversed by both novel and standard PF. However, the novel PF, but not standard PF, completely suppressed TNF-α, IL-6 and IL-8 levels from cultured biopsies. CONCLUSIONS: Newly developed nutritional formula reproducibly ameliorated DSS-induced colitis in a murine model, although this response was not measurably different to standard PF. However, the novel PF was significantly superior in suppressing inflammatory cytokine release from cultured colonic biopsies. Collectively, these findings support a possible role for novel PF in advancing nutritional therapy for CD patients.

Can the need for palliative transurethral prostatic resection in patients with advanced carcinoma of the prostate be predicted?

PURPOSE: To identify the factors predicting the need for palliative transurethral resection of the prostate (channel TURP) in patients with advanced carcinoma of the prostate (CAP) receiving androgen ablation therapy. PATIENTS AND METHODS: From January 1996 to January 2004, 203 patients with advanced CAP were treated by androgen ablation. Patients presenting with retention were catheterized initially, and those (N = 12) who failed a catheter-free trial and had immediate channel TURP were excluded. The remaining 191 patients were followed every 3 months (mean 35.5 months, range 6-92 months). Patients requiring channel TURP (group 1; N = 42 [22%]) during follow-up were compared with those who did not (group 2) for predictive factors, viz. retention of urine, serum prostate specific antigen (PSA) concentration, Gleason sum, prostate size, and bony metastasis at presentation. RESULTS: Channel TURP was performed at a mean of 21 months (range 3-72 months). The mean Gleason sum in this group was 7.88, whereas it was 7.29 in group 2 (P = 0.013). Retention at presentation was significantly more common in group 1 (N = 26; 61.9%) than in group 2 (N = 46; 30.8%; P = 0.001). Patients who did not present with retention and had Gleason sums < or =7 (N = 32) did not require channel TURP. Of the 14 patients who voided successfully after a catheter-free trial but had Gleason sums of >7, 71.4% required channel TURP. Other factors were not found to be significantly different in the two groups. CONCLUSION: High Gleason sum and retention at presentation are significant factors predictors of the need for channel TURP during follow-up in patients with advanced CAP receiving androgen ablation therapy.